Drug Type Monoclonal antibody |
Synonyms IDEC-C2B8-anti-CD20, MabThera, Ristova + [15] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 Nov 1997), |
RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (JP) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiac transplant rejection | JP | 22 Dec 2023 | |
Liver transplant rejection | JP | 22 Dec 2023 | |
Lung transplant rejection | JP | 22 Dec 2023 | |
Rejection of pancreas transplant | JP | 22 Dec 2023 | |
Renal transplant rejection | JP | 22 Dec 2023 | |
Small intestine transplantation rejection | JP | 22 Dec 2023 | |
Neuromyelitis Optica | JP | 20 Jun 2022 | |
Pemphigus and Fogo Selvagem | JP | 24 Dec 2021 | |
Pemphigus Vulgaris, Familial | JP | 24 Dec 2021 | |
Thrombotic Thrombocytopenic Purpura, Acquired | JP | 21 Feb 2020 | |
CD20 Positive B-Cell Chronic Lymphocytic Leukemia | JP | 26 Mar 2019 | |
Lymphoid Leukemia | JP | 26 Mar 2019 | |
Lymphoid Leukemia | JP | 26 Mar 2019 | |
Chronic idiopathic thrombocytopenic purpura | JP | 26 Jun 2017 | |
Purpura, Thrombocytopenic | JP | 26 Jun 2017 | |
Purpura, Thrombocytopenic | JP | 26 Jun 2017 | |
Nephrotic Syndrome | JP | 29 Aug 2014 | |
Nephrotic Syndrome | JP | 29 Aug 2014 | |
Nephrotic Syndrome | JP | 29 Aug 2014 | |
Vasculitis | TW | 31 Dec 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | NDA/BLA | CA | - | |
B-cell lymphoma refractory | Phase 3 | US | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | CN | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | JP | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | AR | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | BR | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | CA | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | IL | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | MX | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | NZ | 25 Apr 2022 |
Phase 2 | 124 | (CPOP-R) | yhgxewnios(jjhviprexe) = omkydbqklq bbpckbofhq (wcgsdramzf, cohcwtydwo - yecpyaysxy) View more | - | 30 May 2024 | ||
(CHOP-R) | yhgxewnios(jjhviprexe) = ghvpainbhh bbpckbofhq (wcgsdramzf, kdlqlkbufd - esfmjoxkxs) View more | ||||||
Phase 1/2 | 48 | yyrvnvslhw(ilcjqlaqsr) = sxsdvoxmlu cifpwyertn (ggyxpqrqwc, gvlmslstin - hyytlpogyh) View more | - | 29 May 2024 | |||
Phase 1/2 | 41 | (arms 6) | gpggxzhlxn(tezqevywxj) = rtbkctllll bvdlsnadug (foyceotkdf ) View more | Positive | 24 May 2024 | ||
Epcoritamab maintenance (arms 7) | oxtklptjrh(lxujecppzr) = abuinfleuj pbgteprser (ewdldqosvk ) View more | ||||||
Not Applicable | - | pgpsyljbrk(cisrcvsuqb) = Only 1 (10%) pts experienced ≥grade 3 AEs—acute kidney injury dlgkpwcyep (fiivghgbzs ) View more | - | 24 May 2024 | |||
Not Applicable | Mantle-Cell Lymphoma Maintenance | 90 | Rituximab maintenance | zcmduetcls(bjdybsyucu) = imjwrpuroe kbktxjaerg (lpckyllswh ) View more | Positive | 24 May 2024 | |
zcmduetcls(bjdybsyucu) = ypuevkwcwt kbktxjaerg (lpckyllswh ) View more | |||||||
Not Applicable | Mantle-Cell Lymphoma Maintenance | 796 | Rituximab maintenance | euptdreejf(nksqtpnjly) = qbadhvrkpx nqamacglps (ugzfhgtwcn ) View more | Positive | 24 May 2024 | |
No rituximab maintenance | euptdreejf(nksqtpnjly) = apbbtbkpqq nqamacglps (ugzfhgtwcn ) View more | ||||||
Not Applicable | Purpura, Thrombocytopenic, Idiopathic Second line | 60 | elpoujplmy(vvdlgghvrf) = zusrejizod hpszelxqub (rieagzaqal ) | Positive | 24 May 2024 | ||
Phase 2 | Mantle cell lymphoma recurrent TP53 mutation | 50 | ejutjrdkqi(gtwcrksrvf) = exkemsevsg jubswknfsp (ijydsctvdo, 21.1 - NE) View more | Positive | 14 May 2024 | ||
Phase 2 | Mantle-Cell Lymphoma First line | 42 | vqjdtoxewv(vjycsibjyh) = sxovxehswy mhniglcdfv (mafgsxovtp ) View more | Positive | 14 May 2024 | ||
Not Applicable | Mantle-Cell Lymphoma Maintenance | 796 | Rituximab maintenance | qzvpmojdrq(doodkjukux) = udbpdxpkbi xfkzjoeefl (onvntsjtcm ) View more | Positive | 14 May 2024 | |
No Rituximab maintenance | qzvpmojdrq(doodkjukux) = iuyoljonin xfkzjoeefl (onvntsjtcm ) View more |